Global Chronic Pulmonary Hypertension Treatment Industry to Expand Significantly, Forecasted to Hit US$ 11.4 Billion by 2033 | FMI

Future Market Insights, a leading market research firm, has recently released a comprehensive study forecasting a significant surge in the Global Chronic Pulmonary Hypertension Treatment Industry. The market, currently valued at US$ 7 billion in 2023, is expected to witness a robust CAGR of 5%, reaching a remarkable US$ 11.4 billion by the year 2033.

The research highlights the escalating prevalence of pulmonary hypertension and the growing accessibility to effective treatment options as key drivers propelling the market’s exponential growth over the next decade. The Chronic Pulmonary Hypertension Treatment Market is poised to become a crucial player in the healthcare landscape, providing innovative solutions for those affected by this disorder.

Request a Sample Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16779

The increasing incidence of the disease is one of the primary drivers of the chronic pulmonary hypertension therapy industry. According to the Pulmonary Hypertension Association, pulmonary hypertension affects 10-15% of patients with chronic obstructive pulmonary disease (COPD) and 30-40% of individuals with idiopathic pulmonary fibrosis (IPF). Pulmonary hypertension is also more common in persons with connective tissue illnesses such as scleroderma and lupus.

The availability of effective treatment choices is another factor driving the growth of the Chronic Pulmonary Hypertension Treatment market. Several medications, including prostacyclins, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors, have been approved by regulatory authorities for the treatment of pulmonary hypertension. These drugs act by dilating the blood arteries in the lungs, lowering pulmonary artery pressure, and increasing blood flow.

Furthermore, rising pulmonary hypertension awareness among healthcare professionals and patients is expected to drive demand for effective treatment options. Pulmonary hypertension is frequently misdiagnosed or underdiagnosed, therefore raising awareness of the disease can help patients obtain timely and effective treatment.

Key Takeaways from the Global Chronic Pulmonary Hypertension Treatment Industry Study

  • From 2018 to 2022, the Chronic Pulmonary Hypertension Treatment market grew at a CAGR of 3.5%.
  • The global Chronic Pulmonary Hypertension Treatment market is expected to grow with a 5% CAGR during 2023 to 2033.
  • As of 2033, the Chronic Pulmonary Hypertension Treatment Market is expected to reach US$ 11.4 Billion.
  • According to the FMI analysis, the oral route of administration accounts for the largest market share.
  • North America is expected to possess 40% market share for the Chronic Pulmonary Hypertension Treatment market.
  • The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Chronic Pulmonary Hypertension Treatment,” says an FMI analyst

Ask Us Your Questions About This Report

https://www.futuremarketinsights.com/request-discount/rep-gb-16779

Global Chronic Pulmonary Hypertension Treatment Industry Competition

Key players in the market include companies such as Bayer, Attgeno AB, Cereno Scientific AB, Bial – Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmed, Altavant Sciences, Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., along with healthcare providers and technology companies among other global players.

  • In June 2022, Gossamer Bio, Inc., a clinical-stage biopharmaceutical company that specializes in discovering, acquiring, developing, and commercializing therapeutics in the areas of immunology, inflammation, and oncology, announced the release of crucial preclinical data that supports the potential of seralutinib in treating pulmonary arterial hypertension (PAH). The article, titled “Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension,” is available online and will be included in a future printed edition of the European Respiratory Journal, which is the premier scientific journal of the European Respiratory Society.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Chronic Pulmonary Hypertension Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights based on drug type, distribution channel, route of administration & region.

Request Report Customization@
https://www.futuremarketinsights.com/customization-available/rep-gb-16779

Key Segments Profiled in the Global Chronic Pulmonary Hypertension Treatment Industry Survey

By Drug Type:

  • Endothelin Receptor Antagonists
  • PDE-5 Inhibitors
  • Prostacyclin Analogs
  • SGC Stimulators

By Route of Administration:

  • Oral
  • Intravenous/Subcutaneous
  • Inhalational

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Birch Allergy Treatment Industry Predicted to Expand at 7% CAGR, Anticipating US$ 1123.24 Million Value by 2033 | FMI

During the forecast period from 2023 to 2033, the Global Birch Allergy Treatment Industry is poised for substantial growth at a 7% Compound Annual Growth Rate (CAGR), as reported by Future Market Insights. By the year 2033, the global market for Birch allergy treatment is expected to reach a remarkable valuation of US$ 1123.24 Million.

The escalating awareness surrounding allergies and their profound impact on health is a key driver behind the market’s anticipated growth. The rise in the prevalence of allergic reactions has prompted healthcare providers to intensify their focus on allergy prevention and treatment. This trend has led to a surge in individuals seeking medical intervention for various allergies, including those triggered by birch pollen.

Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-16769

In addition to traditional treatment options, there has also been a growing interest in alternative therapies for the treatment of birch allergy. These therapies include acupuncture, herbal remedies, and homeopathy. While the efficacy of these treatments is still being studied, they have shown promising results in some cases and may provide additional treatment options for birch allergy sufferers.

Key Takeaways from the Global Birch Allergy Treatment Industry Study

  • The Birch allergy treatment market is expected to grow at a value of 7% CAGR in the forecast period 2023-2033
  • Oral route of administration is expected to hold 53% of the market share in 2023 for Birch allergy treatment market.
  • North America is expected to possess 48% market share for Birch allergy treatment market in 2023.
  • Europe Birch allergy treatment market size is expected to possess 43% market share in 2023.

“Significant increase in the number of drugs and therapies available for the treatment of birch allergy is not only increasing treatment options for patients but has also has made treatments more effective and efficient.” states an FMI analyst

Reach Out to Our Analyst For Your Queries https://www.futuremarketinsights.com/ask-question/rep-gb-16769

Global Birch Allergy Treatment Industry Competitive Landscape

Key players in the Birch allergy treatment market are Allergy Therapeutics Plc, Regeneron Pharmaceuticals Inc, Desentum, HAL Allergy Group, Roxall Medizin GmbH, Worg Pharmaceuticals AG, S-TARget therapeutics GmbH, Adamis Pharmaceuticals Corporation, Merck KGaA and Stallergenes Greer plc

  • Allergy Therapeutics Plc is a biopharmaceutical company that specializes in developing immunotherapy products for the treatment of allergies, including birch allergy. The company has developed a range of products for the treatment of birch allergy, including subcutaneous and sublingual immunotherapies.
  • Desentum’s product for birch allergy is called ASIT+TM Birch, which is a vaccine that combines Desentum’s proprietary peptide-based technology with an adjuvant to enhance the immune response.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Birch allergy treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

Request Your Customized Report Now! https://www.futuremarketinsights.com/customization-available/rep-gb-16769

The study reveals essential insights based on Drug Class (Antihistamines, Cetirizine, Diphenhydramine, Decongestant, Pseudoephedrine, Oxymetazoline) Route of Administration (Oral, Intranasal), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)

Key Segments Profiled in the Global Birch Allergy Treatment Industry Survey

Drug Class:

  • Antihistamines
  • Cetirizine
  • Diphenhydramine
  • Decongestant
  • Pseudoephedrine
  • Oxymetazoline

Route of Administration:

  • Oral
  • Intranasal

Distribution Channel:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Pediatric Obesity Management Industry Set for 4% CAGR, Envisioned at US$ 4.74 Billion by 2033 | FMI

The Global Pediatric Obesity Management Industry is reaching new heights, emerging as a paramount concern in public health. Recent data from the World Health Organization (WHO) reveals a staggering reality, with approximately 41 million children under the age of five identified as overweight or obese in 2016. Alarming as it is, projections indicate a continued rise in these numbers in the years to come.

Future Market Insights anticipates a transformative journey for the Pediatric Obesity Management Market, forecasting a compelling compound annual growth rate (CAGR) of 4% from 2023 to 2033. This projection underscores the urgency of addressing this global health challenge and highlights the significance of innovative solutions in pediatric obesity management.

Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-16761

One of the most promising innovations in pediatric obesity management is the development of personalized nutrition and exercise plans. These plans take into account a child’s unique needs and preferences, as well as their medical history and any underlying conditions. By tailoring nutrition and exercise recommendations to each individual child, healthcare providers can help children achieve and maintain a healthy weight sustainably.

Another promising innovation is the use of digital health tools, such as mobile apps and wearable devices, to monitor and manage pediatric obesity. These tools can help children and their families track their progress, set goals, and receive personalized feedback and support. By making it easier and more convenient to manage pediatric obesity, digital health tools are helping to improve patient compliance and outcomes.

Key Takeaways from the Global Pediatric Obesity Management Industry Study

  • The market for paediatric obesity management expanded at a CAGR of 3% between 2018 and 2022.
  • From 2023 to 2033, the global market for paediatric obesity management is anticipated to expand at a 4% CAGR.
  • The Pediatric Obesity Management Market is anticipated to generate US$4.74 billion by 2033.
  • According to the FMI analysis, hospital pharmacies account for the largest market share.
  • In terms of market share for paediatric obesity management, North America is predicted to hold 40% of the market.
  • With a share of 20% throughout the projection period, it is expected that the East & South Asia market would grow considerably.

Reach Out to Our Analyst For Your Queries https://www.futuremarketinsights.com/ask-question/rep-gb-16761

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Pediatric Obesity Management.” says an FMI analyst

Global Pediatric Obesity Management Industry Competition

Key players in the market include companies such as Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., AstraZeneca, Herbalife Ltd., Apollo Endosurgery, Ethicon, Inc., Takeda Pharmaceutical Company, VIVUS Inc., Currax Pharmaceuticals LLC, along with healthcare providers and technology companies among other global players.

  • The U.S. Food and Drug Administration approved the use of Wegovy (semaglutide) injection (2.4 mg once weekly) as a medication for chronic weight control in individuals with obesity or those who are overweight with at least one weight-related disease, such as high blood pressure, high cholesterol, or type 2 diabetes, in June 2021. The medication can be taken along with a lower calorie diet and more exercise. Since 2014, this subcutaneous injection is the first medication to be licenced for managing chronic weight in individuals who are obese or overweight. Patients with a body mass index (BMI) of 27 kg/m2 or above who have at least one weight-related condition, as well as those with a BMI of 30 kg/m2 or more, are advised to use it.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Pediatric Obesity Management market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights based on Drug Class, Route of Administration, Distribution Channel & Region.

Request Your Customized Report Now! https://www.futuremarketinsights.com/customization-available/rep-gb-16761

Key Segments Profiled in the Global Pediatric Obesity Management Industry Survey

Drug Class:

  • Lorcaserin
  • Liraglutide
  • Phentermine
  • Setmelanotide
  • Others

Route of Administration:

  • Oral
  • Injectable

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Nipah Virus (NiV) Infection Testing Industry Eyes Noteworthy 5.2% Growth, Aiming for US$ 3,277.49 Million by 2033 | FMI

The Global Nipah Virus (Niv) Infection Testing Industry is poised for substantial growth during the forecast period from 2023 to 2033, with a projected Compound Annual Growth Rate (CAGR) of 5.2%, according to the latest analysis by Future Market Insights. By 2033, the market is anticipated to reach a staggering valuation of US$ 3,277.49 million.

Nipah virus, a zoonotic virus with the potential to cause severe encephalitis and fatal outcomes in humans, has seen an increasing prevalence worldwide, contributing to the surge in demand for advanced NiV infection testing solutions.

In 2023, the market size for Nipah virus (NiV) infection testing is estimated to be US$ 1,974.17 million, with a forecasted growth to US$ 3,277.49 million by 2033, showcasing a robust CAGR of 5.2%. This growth can be attributed to the imperative need for early detection and control of NiV infection outbreaks.

Request Sample Copy of Report
https://www.futuremarketinsights.com/reports/sample/rep-gb-16756

The Global Nipah Virus (NiV) Infection Testing Industry has become an important part of public health monitoring and disease surveillance for governments, healthcare providers, and the medical community. The NiV infection testing market has seen several advancements over the years. The latest developments include improved nucleic acid-based tests that offer higher accuracy and faster results. This has helped reduce the risk of false positives and enabled healthcare providers to identify infected individuals more quickly.

In addition, the development of point-of-care testing devices for NiV infections has enabled healthcare providers to diagnose patients in remote areas without access to laboratory facilities. This has helped in the early detection and treatment of infected individuals in areas with limited healthcare resources. Furthermore, Asia Pacific along with Middle East and Africa are the largest contributors to the Nipah virus (NiV) infection testing market.

Key Takeaways from the Global Nipah Virus (NiV) Infection Testing Industry Study

  • The Global Nipah Virus (NiV) Infection Testing Industry is expected to grow at a value of 5.2% CAGR in the forecast period 2023 to 2033
  • By end user, hospitals are expected to possess 40% market share for Nipah virus (NiV) infection testing market in 2023.
  • Asia Pacific is expected to possess 45% market share for Nipah virus (NiV) infection testing market in 2023.
  • Middle East and Africa is expected to possess 39% market share for Nipah virus (NiV) infection testing market in 2023.

“The NiV infection testing market provides several benefits to the medical community and the general public. It enables healthcare providers to identify and treat infected individuals quickly and accurately. This helps reduce the spread of the virus and possible complications of the infection.” states an FMI analyst

Grab Your Report on Discount Before It’s Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-16756

Global Nipah Virus (NiV) Infection Testing Industry Competitive Landscape

Key players in the Nipah virus (NiV) infection testing market are Aurobindo, Minapharm, Roche, Lupin Ltd, Siegfried, Vivacure, Starlake Bioscience, Xaretto, Liferiver, MyBioSource, Krishgen Biosystems

  • Aurobindo has developed a rapid diagnostic test for NiV, allowing clinicians to quickly detect the presence of the virus. Additionally, Aurobindo has used its expertise in the field of immunoassay and ELISA development to create an antibody test for NiV.
  • In July 2020, Roche launched the cobas® NiV/HEV Assay. This test is a qualitative in-vitro diagnostic assay that detects NiV and HEV nucleic acid from human specimens and provides results in just under two hours.

Key Segments Profiled in the Nipah Virus (NiV) Infection Testing Industry Survey

Test Type:

  • RT PCR based kits
  • ELISA Kits

End User:

  • Hospitals
  • Research Labs
  • Diagnostic Centres

Request Your Customized Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-16756

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Migraine Treatment Industry to Achieve US$ 4.74 Billion by 2033, Propelled by a Steady 4% Compound Annual Growth Rate | FMI

The Global Migraine Treatments Industry is on the brink of a significant upswing, fuelled by heightened awareness of the condition and notable advancements in treatment options. According to a comprehensive report by Future Market Insights, the market is anticipated to experience a steady compound annual growth rate (CAGR) of 4% from 2023 to 2033.

Migraine, characterized by debilitating headaches and accompanied by symptoms such as nausea, vomiting, and sensitivity to light and sound, imposes a substantial burden on individuals, affecting their work, social activities, and daily routines. The rising prevalence of this condition has spurred research and development efforts, leading to remarkable breakthroughs in migraine treatment.

Recent years have witnessed a paradigm shift in migraine treatment strategies, with the introduction of innovative medications and non-pharmacological approaches. This influx of novel and better-tolerated treatment options is expected to be a key driver behind the projected growth in the migraine treatments market. Patients, seeking more effective solutions, are likely to contribute significantly to the increasing demand for these advanced treatments.

Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-16751

Key Takeaways from the Global Migraine Treatment Industry Study

  • From 2018 to 2022, the migraine treatments market grew at a CAGR of 3%.
  • The Global Migraine Treatment Industry is expected to grow with a 4% CAGR from 2023 to 2033.
  • As of 2033, the migraine treatments Market is expected to reach US$ 4.74 Billion.
  • According to the FMI analysis, hospitals account for the largest market share.
  • North America is expected to possess 40% market share for the migraine treatments market.
  • The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering migraine treatments.” says an FMI analyst

Global Migraine Treatment Industry Competition

Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.

  • In November 2022, A team of researchers at University College London (UCL) developed a novel gene therapy that offers promise in treating neurological and psychiatric disorders. The therapy targets overactive brain cells that are responsible for causing several brain diseases, including epilepsy, by reducing their excitability. By using DNA sequences that control gene expression, the therapy drives the production of molecules that prevent these overactive cells from firing, thereby curbing epileptic seizures. Notably, the technique selectively alters only overactive cells while sparing normally functioning cells.

Reach Out to Our Analyst For Your Queries https://www.futuremarketinsights.com/ask-question/rep-gb-16751

In preclinical studies, the new treatment demonstrated a higher efficacy than previous gene therapies or anti-seizure drugs tested in the same model. The team observed an approximately 80% reduction in spontaneous seizures in epileptic mice treated with the therapy. Furthermore, the researchers believe that this gene therapy has the potential to treat other disorders where some brain cells are overactive, such as Parkinson’s disease.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global migraine treatments market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights based on Drug Class, Route of Administration, Treatment, Distribution Channel & Region.

Key Segments Profiled in the Global Migraine Treatment Industry Survey

Drug Class:

  • Zavegepant
  • Atogepant
  • Zolmitriptan

Route of Administration:

  • Oral
  • Parenteral
  • Nasal Sprays

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Treatment:

  • Abortive Medicine
  • Preventive Medicine

Grab Your Report on Discount Before It’s Gone! https://www.futuremarketinsights.com/request-discount/rep-gb-16751

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Glucose Monitoring Devices Industry Achieves Unprecedented Growth at 16.9% CAGR, set to Surpass US$ 118.1 Billion by 2033 | FMI Reports

According to the latest industry report from Future Market Insights (FMI), the Global Glucose Monitoring Devices Industry, valued at approximately US$ 21.3 Billion in 2022, is poised for remarkable growth, projecting a Compound Annual Growth Rate (CAGR) of nearly 16.9% over the forecast period. FMI anticipates the industry to achieve a staggering estimated worth of US$ 118.1 Billion by the year 2033.

The surge in the Global Glucose Monitoring Devices Industry comes at a crucial time as diabetes has emerged as a severe global health concern over the past two decades. With an unprecedented rate of global growth, diabetes has become a significant contributor to mortality, particularly in the age group of 20 to 79. The World Health Organization has classified diabetes as a global pandemic, underscoring its rapid and widespread prevalence.

One of the key contributors to the escalating costs associated with diabetes management is the need for regular monitoring. FMI’s report emphasizes that leveraging technologies such as information and communication, artificial intelligence, and smart devices can play a pivotal role in reducing these monitoring costs.

The adoption of continuous glucose monitoring devices, which are emerging as a novel technique for monitoring glucose levels, is growing along with the number of diabetic patients. Every ten minutes, these devices update the real-time glucose level data they provide. The preservation of healthy blood glucose levels is the only method for a diabetic to prevent potentially fatal diabetic complications, and glucose monitoring is an essential component of diabetes management.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16747

Non-invasive glucose monitoring has recently become more popular as it lessens the discomfort and suffering experienced by diabetics who must prick their skin more than four times per day to measure their blood glucose levels.

With the increasing prevalence of diabetes, as well as advancements in sensor-based technologies for patient monitoring, the market is set to expand at a lucrative pace, over the forecast period.

Key Takeaways from Global Glucose Monitoring Devices Industry Study

  • Self-monitoring devices are the leading segment as a product, and hold approximately 3% market value share in 2022, owing to their automated and reliable monitoring process.
  • The diabetes type II segment is set to lead in terms of indication of glucose monitoring devices with an estimated market value share of around 1% by 2023, owing to the high prevalence of type II diabetes globally.
  • By end users, hospitals held a market share of around 7% in 2022, owing to the adoption of continuous monitoring devices in hospitals to reduce the number of fingersticks point-of-care capillary blood glucose tests, hyperglycemic episodes, and hypoglycemic episodes.
  • North America holds a value share of 0% in 2022, owing to the high prevalence of chronic diseases in the region.

Reach Out to Our Analyst For Your Queries
https://www.futuremarketinsights.com/ask-question/rep-gb-16747

“Rising initiatives to integrate artificial intelligence, as well as digital technologies to blood glucose monitoring devices, as well as growing new product launch activities, are factors propelling the growth of the global glucose monitoring market,” says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)

Global Glucose Monitoring Devices Industry Competition

Key players’ rigorous research led to the development of improved technologies such as flash glucose monitoring and continuous glucose monitoring. Companies also engage in strategic initiatives such as new product launches and mergers and acquisitions.

  • All consumers with diabetes type 1 are now covered by the Dexcom G6 rtCGM System under the Non-Insured Health Benefits Program, according to an announcement made by Dexcom, Inc. in January 2023.
  • Abbott disclosed in June 2022 that it is creating a new wearable that combines a sensor to continually monitor both glucose and ketone levels. The U.S. FDA has granted the system breakthrough device classification.

Key Global Glucose Monitoring Devices Industry Players:

  • Dexcom, Inc.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Medtronic
  • Ascensia Diabetes Care
  • Arkray
  • Ypsomed AG
  • Acon Laboratories
  • Nipro
  • Nova Biomedical
  • Goldsite Diagnostics Inc. (China)
  • Lifescan Ip Holdings, LLC
  • Prodigy Diabetes Care
  • Others

Click Here To Buy Your Full Report
https://www.futuremarketinsights.com/checkout/16747

Key Market Segments Covered in Global Glucose Monitoring Devices Industry Research

Product:

  • Self-Monitoring Devices
  • Continuous Monitoring Devices

Indication:

  • Diabetes Type I
  • Diabetes Type II

End User:

  • Hospitals
  • Clinics
  • Diagnostics Centres
  • Home Care Settings

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Gene Therapy in CNS Disorder Industry to Hit a Record US$113.04 Billion by 2033, Driven by remarkable a 30% CAGR | FMI Findings

The Global Gene Therapy in CNS Disorder Industry is poised for an unprecedented surge, with projections indicating a remarkable growth trajectory. According to industry forecasts, the market is expected to achieve a value of US$ 8.2 billion in 2023, catapulting to an astounding US$ 113.04 billion by 2033. This remarkable ascent is underpinned by a compound annual growth rate (CAGR) of 30% anticipated between 2023 and 2033, following a robust CAGR of 19% during the period from 2018 to 2022.

The driving force behind this exponential growth is the escalating prevalence of CNS disorders, particularly neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. As the global population ages, the incidence of these conditions is on the rise, presenting a substantial healthcare burden and intensifying the demand for effective treatments.

Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-16744

Moreover, the growing investment in gene therapy research and development is expected to hasten the development of new therapies for CNS disorders. Regulatory agencies such as the FDA have created accelerated pathways for the approval and review of gene therapy treatments, facilitating faster development and commercialization of these therapies.

Key Takeaways from the Global Gene Therapy in CNS Disorder Industry Study

  • The Gene Therapy in CNS Disorder market increased at a 19% CAGR from 2018 to 2022.
  • From 2023 to 2033, the global Gene Therapy in CNS Disorder market is predicted to develop at a 30% CAGR.
  • The Gene Therapy in CNS Disorder Market is anticipated to reach US$ 113.04 billion by 2033.
  • Hospitals have the biggest market share, according to the FMI research.
  • North America is estimated to have 40% of the market for Gene Therapy in CNS Disorders.
  • The East & South Asia market is expected to grow significantly throughout the forecast period, accounting for 20% of the total. 

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fuelling further clinical trials and research studies dedicated to discovering Gene Therapy in CNS Disorder.” says an FMI analyst

Grab Your Report on Discount Before It’s Gone! https://www.futuremarketinsights.com/request-discount/rep-gb-16744

Global Gene Therapy in CNS Disorder Industry Competition

Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.

  • In November 2022, A team of researchers at University College London (UCL) developed a novel gene therapy that offers promise in treating neurological and psychiatric disorders. The therapy targets overactive brain cells that are responsible for causing several brain diseases, including epilepsy, by reducing their excitability. By using DNA sequences that control gene expression, the therapy drives the production of molecules that prevent these overactive cells from firing, thereby curbing epileptic seizures. Notably, the technique selectively alters only overactive cells while sparing normally functioning cells.

In preclinical studies, the new treatment demonstrated a higher efficacy than previous gene therapies or anti-seizure drugs tested in the same model. The team observed an approximately 80% reduction in spontaneous seizures in epileptic mice treated with the therapy. Furthermore, the researchers believe that this gene therapy has the potential to treat other disorders where some brain cells are overactive, such as Parkinson’s disease.

More Insights Available

North America is projected to dominate the Gene Therapy market due to the presence of a well-established healthcare infrastructure, significant investment in gene therapy research and development, and favorable regulatory policies. The United States is expected to contribute the most significant share of the market due to its advanced healthcare system and high incidence of CNS disorders.

Request Your Customized Report Now! https://www.futuremarketinsights.com/customization-available/rep-gb-16744

Key Segments Profiled in the Global Gene Therapy in CNS Disorder Industry Survey

Indication:

  • Alzheimer’s Disease
  • Huntington’s Disease
  • Parkinson’s Disease
  • Batten Disease

Type:

  • Ex Vivo
  • In Vivo

End User:

  • Hospitals
  • Specialty Clinics

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Cocaine Intoxication Treatment Industry Set to Eclipse US$ 17.91 Million with 6% CAGR by 2033 | FMI Analysis Reveals

The Global Cocaine Intoxication Treatment Industry is poised for substantial expansion over the next decade, driven by the escalating prevalence of cocaine addiction. A recent report by Future Market Insights (FMI) predicts a noteworthy Compound Annual Growth Rate (CAGR) of 6% from 2023 to 2033, culminating in a remarkable valuation surpassing US$ 17.91 Million.

Cocaine addiction is an alarming public health challenge, impacting millions worldwide and giving rise to concerns related to overdose risks, mental health implications, and broader societal consequences. Despite the absence of FDA-approved medications exclusively designed for treating cocaine intoxication, healthcare professionals currently deploy various off-label medications and diverse therapeutic approaches to address symptoms and facilitate addiction recovery.

Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-16738

The market for cocaine intoxication treatment includes medications, behavioral therapies, and other interventions designed to support recovery from cocaine addiction and manage the symptoms of intoxication. The global prevalence of cocaine use disorder has been increasing in recent years, with the United States and Europe experiencing significant increases in cocaine-related deaths. This trend is expected to drive demand for cocaine intoxication treatment and support market growth.

Key Takeaways from the Global Cocaine Intoxication Treatment Industry Study

  • The Cocaine Intoxication Treatment market expanded at a CAGR of 4% from 2018 to 2022.
  • From 2023 to 2033, the market for treating cocaine intoxication is projected to expand at a 6% CAGR.
  • The market for treating cocaine intoxication is anticipated to reach US$17.91 million by 2033.
  • Hospital pharmacies hold the biggest market share, per the FMI research.
  • For the Cocaine Intoxication Treatment market, North America is anticipated to have a 40% market share. With a share of 20% throughout the projection period, it is expected that the East & South Asia market would grow considerably.
  • The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Cocaine Intoxication Treatment.” says an FMI analyst

Global Cocaine Intoxication Treatment Industry Competition

Key players in the market include pharmaceutical companies such as Tonix Pharmaceutical, GlaxoSmithKline Plc., Bristol Myers Squibb Company, Pfizer Inc., Novartis AG, Teva Pharmaceuticals Ltd., Zydus Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd., and Advanz Pharmaceuticals, along with healthcare providers and technology companies among other global players.

  • Tonix Pharmaceuticals Holding Corp. was awarded a grant in August 2022 by the National Institute on Drug Abuse to aid the advancement of TNX-1300, a recombinant enzyme that targets the treatment of cocaine intoxication. Cocaine abuse can have harmful impacts on multiple bodily systems, primarily the cardiovascular system, and can lead to fatal consequences. TNX-1300 has been demonstrated to counteract the physiological consequences of intravenous cocaine use in previous clinical research. This grant will assist in the ongoing development of TNX-1300 as a treatment for life-threatening cocaine intoxication, which was responsible for more than 24,900 drug overdose fatalities in the United States in 2021.

Click Here to Request Methodology! https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16738

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Cocaine Intoxication Treatment market, presenting a historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights based on Drug Class, Route Administration, Distribution Channel & Region.

Key Segments Profiled in the Global Cocaine Intoxication Treatment Industry Survey

Drug Class:

  • Phentolamine
  • Lorazepam
  • Diazepam
  • Verapamil
  • Morphine

Route of Administration:

  • Oral
  • Inhalation
  • Intravenous
  • Nasal

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

 Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Whim Syndrome Management Industry Gains Momentum, Anticipates US$ 17.91 Million Value by 2033, Driven by a Sustainable 6% CAGR | FMI

The Global Whim Syndrome Management Industry is currently in its infancy, but it is expected to grow significantly in the coming years. The increasing prevalence of Whim Syndrome, coupled with the growing demand for effective treatment options, is driving the growth of this market. According to a new market research report published by Future Market Insights, the global Whim Syndrome market is projected to reach a value of $10 million by 2023, growing at a CAGR of 6% during the forecast period, surpassing US$ 17.91 Million valuations by 2033.

One of the key factors driving the growth of the Whim Syndrome market is the increasing prevalence of this rare genetic disorder. Although Whim Syndrome is a rare disorder, the incidence of this condition is increasing. According to the National Organization for Rare Disorders (NORD), the incidence of Whim Syndrome is estimated to be around 1 in every 50,000 to 100,000 people worldwide.

Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-16737

Another factor driving the growth of the Whim Syndrome market is the increasing demand for effective treatment options. Currently, there are no approved treatments for Whim Syndrome. However, several companies are developing potential therapies for this rare disorder, and many of these treatments are in the late stages of clinical development.

In conclusion, the Whim Syndrome market is expected to grow significantly in the coming years, driven by the increasing prevalence of this rare genetic disorder and the growing demand for effective treatment options. As more treatments become available for Whim Syndrome, the demand for these treatments is expected to increase, driving the growth of this market.

Key Takeaways from the Market Study

  • From 2018 to 2022, the Whim Syndrome Management market grew at a CAGR of 4%.
  • The global Whim Syndrome Management market is expected to grow with a 6% CAGR during 2023 to 2033.
  • As of 2033, the Whim Syndrome Management Market is expected to reach US$ 17.91 Million.
  • According to the FMI analysis, hospital pharmacies account for the largest market share.
  • North America is expected to possess 40% market share for the Whim Syndrome Management market.
  • The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

Ask Us Your Questions About This Report https://www.futuremarketinsights.com/ask-question/rep-gb-16737

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fuelling further clinical trials and research studies dedicated to discovering Whim Syndrome Management.” says an FMI analyst

Market Competition

Key players in the market include pharmaceutical companies such as X4 Pharmaceuticals, National Institute of Allergy and Infectious Diseases, GSK plc, Bristol Myers Squibb Company, F-Hoffmann La Roche Ltd., Pfizer Inc., Johnson and Johnson Services, Inc., Horizon Therapeutics plc, Amgen, and Leadiant Biosciences along with healthcare providers and technology companies among other global players.

  • Under the guidance of Philip Murphy, M.D. and David McDermott, M.D., researchers from the IRP have identified and enrolled three patients with advanced WHIM syndrome, who were ineligible for standard treatment, in an open-label study. These patients were administered low doses of plerixafor, and all three experienced a reduction in infection frequency and a significant enhancement in their quality of life. The utilization of plerixafor to treat WHIM syndrome is a new approach for patients who are unable to manage their symptoms using traditional therapies. Consequently, a randomized, double-blind Phase 3 trial has been developed to compare plerixafor to standard treatment, evaluate its clinical effectiveness, and gather additional safety information. You can find this trial on ClinicalTrials.gov with the identifier NCT02231879.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Whim Syndrome Management market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Drug Class, Route Administration, Distribution Channel & Region.

Grab Your Report on Discount Before It’s Gone! https://www.futuremarketinsights.com/request-discount/rep-gb-16737

Key Segments Profiled in the Whim Syndrome Management Industry Survey

Drug Class:

  • Mavorixafor
  • Plerixafor

Route of Administration:

  • Oral
  • Parenteral
  • Injectable

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Discrete Analyzers Industry Anticipated to Scale Heights of $2.6 Billion by 2033, Fueled by 5.2% CAGR | FMI

According to Future Market Insights’ latest industry analysis, the market size for the Global Discrete Analyzers Industry is expected to reach US$ 1.5 Billion in 2023. It is projected to exhibit growth at a CAGR of 5.2% over the forecast period, with an estimated market size of ~US$ 2.6 Billion in 2033.

High levels of air pollution and nutrient discharges from agriculture and wastewater continue to harm ecosystems, reduce agricultural production, and cause eutrophication and acidification. It is anticipated that pollution will significantly rise over the ensuing decades directly affecting human health and having an impact on ecosystems, soil, water, and air. Thus, increasing pollution will grow the demand for discrete analyzers in the market.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-7026

Cross-contamination and detection issues caused by frequent washing and reuse of cuvettes or by cleaning the liquid channel inside a flow cell are eliminated when using disposable cuvettes. This advantage of discrete analyzers results in the high usage of discrete analyzers.

The government’s goal is to broaden the scope of pollution monitoring, not to replace or displace current laboratories. The discrete analyzer technique will contribute to expanding the reach of environmental laboratories.

Companies involved in the global discrete analyzers market are actively working to improve their competitiveness through new product introductions, business expansion, regulatory clearances, partnerships, and agreements with both established and emerging competitors.

Acquisitions and mergers significantly accelerate a manufacturer’s ability to capture a significant share of the market. Some of the recent instances of this trend are:

Key Takeaways from Global Discrete Analyzers Industry Study

  • Discrete analyzers system held a 6% market share in the product segment of the global discrete analyzers market in 2022, owing to excellent product quality and accuracy.
  • Bench top discrete analyzers accounted for 4% of the global market share in the modality segment of the global discrete analyzers market in 2022. This is because these analyzers perform different tests quickly on a variety of samples.
  • Environmental testing labs segment held a share of 3% of the end-user category of the global discrete analyzers market in 2022, due to the serious global contamination incidents.
  • North America held a market share of 4% in 2022, owed to the high prevalence of waterborne diseases.

“Increasing Prevalence of Water Borne Diseases and the Advancements in Terms of Technology used in Water Quality Monitoring is set to Propel Sales of the Discrete Analyzers Market across the Globe,” says an analyst of Future Market Insights.

Click Here to Request Methodology!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-7026

Global Discrete Analyzers Industry Competition    

The discrete analyzers market is highly fragmented because of the large number of players in the market both local and international. There is a broad range of products that can be categorized under the discrete analyzers market, making it a broad market. The strategies that are majorly followed by the key players of the discrete analyzers market include product launches and expansions.

  • In August 2022, Abbott Laboratories, a major U.S. provider of medical technology, is investing 440 million euros in Ireland to create new jobs in Donegal and a sizable new manufacturing facility in Kilkenny.
  • In Jan 2020, the suPARnostic® TurbiLatex product from ViroGates received regulatory approval (CE-IVD) for use with Siemens Healthineers’ ADVIA® Chemistry XPT System. The suPARnostic® TurbiLatex solution from ViroGates is now available for clinical regular usage in hospitals using ADVIA XPT systems.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the discrete analyzers market in its latest study, presenting a historical demand assessment of 2017 – 2022 and projections for 2023 – 2033. The global discrete analyzers market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The research study is based on the product (discrete analyzer systems [<140 tests, 150- 200 tests capacity, 201-450 tests capacity, 410-600 and more tests capacity], consumables [cuvettes, reagents, and coils], and software), by modality (standalone discrete analyzers and bench top discrete analyzers), by end-user (wastewater plants, general testing labs, environmental testing labs, agriculture, and food testing labs, pharmaceutical companies, government, and academic institutes and laboratories, and contract research organization), across seven key regions of the world.

Key Companies Profiled in the Global Discrete Analyzers Industry     

  • Thermofisher Scientific Inc.
  • Seal Analytical
  • Skalar Analytical B.V.
  • Chinchilla Scientific
  • SYSTEA S.p.a
  • Astoria-Pacific, Inc.
  • Siemens Industry, Inc.
  • NECi Superior Enzymes
  • Abbott Laboratories
  • Roche Holding AG
  • KPM Analytics

Buy a Complete Research Report
https://www.futuremarketinsights.com/checkout/7026

Key Market Segments Covered in Global Discrete Analyzers Industry Research

Product:

  • Discrete Analyzer System
    • <140 Tests Capacity
    • 150-200 Tests Capacity
    • 201-450 Tests Capacity
    • 451-600 and more Tests Capacity
  • Consumables
    • Cuvettes
    • Reagents
    • Coils
  • Software

Modality:

  • Standalone discrete Analyzers
  • Bench Top Discrete Analyzers

End User:

  • Waste Water Plants
  • General Testing Labs
  • Environmental Testing Labs
  • Agriculture and Food Testing Labs
  • Pharmaceutical Companies
  • Government and Academic Institutes and Laboratories
  • Contract Research Organization

Region:

  • North America
  • Latin America
  • Europe
  • South Asia and Pacific
  • East Asia
  • Middle East and Africa

About Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business.

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube